OBIO’s 2019 report describes an early adopter model to facilitate the evaluation and adoption of innovative health technologies in Ontario health organizations.
OBIO’s report, Realizing the Promise of Health Care Innovation: Increasing Value for the Patient, Health System and Economy, was published in 2013 and is a product of the Ontario Bioscience Economic Strategy Team (OBEST®), an initiative launched by OBIO to address the challenges faced by Ontario’s human health technology and bioscience industry.
OBIO’s 2018 Industry Consultation reports five recommendations from health science company executives on how to create the conditions for the growth of Ontario’s health science industry.
On April 9, 2018, OBIO hosted Pfizer Global for a workshop and partnering day at ONRamp in the Banting Institute.
OBIO and Blakes hosted OBIO's third annual pre-RESI networking event, connecting high potential companies with global investors. Over 100 international investors, local investors and strategics, as well as executives from high potential Ontario health science companies
Bridging the Talent Gap reports on the unique value of OBIO’s Health to Business Bridge (H2BB) business internship program. This report describes how H2BB addresses the challenge of pulling top talent into Ontario’s health science industry to address the talent gap identified by 96% of Ontario’s health science company CEOs.
On October 24th, OBIO hosted Health Economics Day workshop in partnership with St. Michael’s Hospital.
The workshop took place in the auditorium at the Li Ka Shing Knowledge Institute and featured four sessions: a moderated panel discussion with four panellists, followed by three presentations by three health economics experts.
Recently, the Minister of Innovation, Science and Economic Development launched a cross country tour to introduce the nine supercluster proposals that have been shortlisted by the federal government for the Innovation Superclusters Initiative.
Grant Burns, OBIO's Public Affairs and Communications Manager, has listed the 9 proposals and provided commentary and analysis on how they relate to the health technology sector.
On October 2nd, Andrew Hutchinson, External Research & Scouting Lead for Alexion Pharmaceuticals, provided his insights on the strategic partnering process between early stage therapeutic companies and big pharma to the OBIO community.
OBIO's Dr. Klaus Fiebig, VP Strategic Programs, recently attended an insightful workshop on the upcoming regulatory changes affecting the CE mark. Obtaining the CE mark is a "mandatory hurdle" to access the $56B EU market, and the new regulatory changes present an opportunity for medical device companies.
Should these changes adjust your CE mark milestones? Read the Klaus' analysis and decide.
On July 11th, Grant Blevins of FCA Venture Partners in Nashville Tennessee, returned to OBIO via webinar to give his second workshop on digital health. Grant focused on the "Why, When, & How Much" that early stage companies should consider when raising capital.
In the latest issue of Biotechnology Focus, OBIO President and CEO Gail Garland contributed a special report.
Anchor Companies and 'Sticky Capital': A prescription for attracting bioscience investment to Ontario
Gail Garland, President and CEO of OBIO, travelled to San Diego for BIO 2017, one of the largest annual conventions in the biotechnology industry.